Episode Details

Novo Nordisk is launching Extensior, a more affordable version of Ozempic in South Africa, set for July 27th with official approval from the SAHPRA. Made by Novo Nordisk itself, it uses the same semaglutide ingredient and comes in the same dosages — aiming to dramatically expand access to diabetes and weight loss treatment without compromising quality. Prices are still being finalized but will be lower than branded semaglutide. Partnering with Acino, Novo Nordisk is targeting broader distribution to meet soaring demand and tackle the grey market that emerged with earlier drugs like Wegovy and Mounjaro.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/7575e023fcb29405